Panitumumab

🧮 Dose calculator

Colorectal cancer · Regimen source: FDA Vectibix · 2

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Vectibix · 2
• • Infuse over 60 min (≤1000 mg) or 90 min (>1000 mg). KRAS G12C: with sotorasib. FDA Vectibix · 2

Enter age and weight.

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Vectibix · 8.1

  “Risk Summary Based on data from animal studies and its mechanism of action, Vectibix can cause fetal harm when administered to pregnant women [see Clinical Pharmacology (12.1) ] .”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Vectibix · 8.2

  “Because of the potential for serious adverse reactions in breastfed infants from Vectibix, advise women not to breastfeed during treatment with Vectibix and for 2 months after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Vectibix · 8.4

  “The safety and effectiveness of Vectibix have not been established in pediatric patients.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Vectibix · 8.5

  “No overall differences in safety or efficacy were observed in elderly patients (≥ 65 years of age) treated with Vectibix monotherapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Vectibix · 8.3

  “Contraception Females Vectibix can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”